Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ABUSthis companyArbutus Biopharma Corp	$3.67	-28.29×	12.04×	65.44×	-27.47×	-163.1%	97.4%	-192.1%	-237.9%	-43.7%	-30.3%	-4.3%	0.05×	0.42×	-278.88×	15.73×	0.0%	5	28.57	4	A-
ALGSAligos Therapeutics, Inc.	$4.38	-3.8×	1.72×	42.14×	-3.45×	-97.4%	57.5%	-4024.9%	-1106.7%	-45.2%	-123.9%	-90.0%	0.1×	0.57×	0×	3.9×	0.0%	2	-16.11	2	C
ALNYAlnylam Pharmaceuticals, Inc.	$155.89	166.38×	66.01×	14.03×	81.9×	-1017.9%	81.8%	13.5%	8.4%	39.8%	13.7%	0.9%	1.62×	-0.6×	1.99×	2.76×	0.0%	5	3.79	4	A-
ARWRArrowhead Pharmaceuticals, Inc.	$47.49	-2,827.05×	9.9×	5.56×	28.84×	-253.1%	100.0%	11.9%	-0.2%	-0.3%	4.6%	3.4%	0.79×	0.85×	1.1×	4.86×	0.0%	3	2.67	1	D+
ASMBAssembly Biosciences, Inc.	$20.95	-61.84×	1.84×	5.27×	-54.31×	-382.4%	99.8%	-16.8%	-8.5%	-3.0%	-5.8%	-10.8%	0.01×	9.31×	0×	5.22×	0.0%	2	7.22	2	B-
AVIRAtea Pharmaceuticals, Inc.	$4.42	-1.84×	1.06×	0×	-1.19×	-75.3%	0.0%	0.0%	0.0%	-57.5%	-63.0%	-45.4%	0×	0.58×	0×	7.82×	0.0%	2	1.99	3	B-
Peer median	—	-3.8×	1.84×	5.56×	-1.19×	-253.1%	81.8%	0.0%	-0.2%	-3.0%	-5.8%	-10.8%	0.1×	0.58×	0×	4.86×	0.0%	2	2.67	2	—